GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC), by way of a plan of arrangement in accordance with Section 192 of the .
(Alliance News) - GSK PLC on Wednesday said it completed its acquisition of Quebec-based late-stage biopharmaceutical firm Bellus Health Inc for a total equity value of USD2.0 billion.
GSK, the Brentford, London-based pharmaceutical company, back in Apr.
The US$14.75-a-share deal, which goes to the Quebec Superior Court next week for approval, is the latest in a series of US$1-billion-plus takeovers of Canadian life sciences companies
European regulators have approved the
region s first vaccine for respiratory syncytial virus ,
which causes thousands of hospitalisations and deaths annually. The shot, called Arexvy, is. | June 7, 2023
EU approves its first vaccine for common respiratory virus von.gov.ng - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from von.gov.ng Daily Mail and Mail on Sunday newspapers.